Filter by: patients
Home > Community Treatment Reports and Side Effects > Zovia 1/35 Treatment Report
What is Zovia 1/35?

Zovia® is a brand name product that combines ethinyl estradiol and ethynodiol diacetate. It is used for pregnancy prevention and off label for treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; and dysfunctional uterine bleeding.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Birth control 3 2 Efficacy_major
General health 1 0

See all 2 patients currently taking Zovia 1/35

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 1
None
 1

Commonly reported side effects, conditions, and hospitalizations associated with Zovia 1/35

Weight gain 1

Reported Dosages

  35 mcg-1 mg daily
  2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Zovia 1/35 (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 2   Other: 100%

See all 2 patients who’ve stopped taking Zovia 1/35

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Zovia 1/35

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Zovia 1/35

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Zovia 1/35

Always
 2 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Zovia 1/35

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 2 100%

Cost

Paid out of pocket

Cost of Zovia 1/35

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 28, 2012.